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Introduction: Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor
positive breast carcinoma, and are known to induce bone density loss and increase the risk of fractures. The
current standard-of-care screening tool for fracture risk is bone mineral density (BMD) by dual-energy X-ray
absorptiometry (DXA). The fracture risk assessment tool (FRAX®) may be used in conjunction with BMD to
identify additional osteopenic patients at risk of fracture who may beneﬁt from a bone-modifying agent (BMA).
The trabecular bone score (TBS), a novel method of measuring bone microarchitecture by DXA, has been shown
to be an independent indicator of increased fracture risk. We report how the addition of TBS and FRAX®,
respectively, to BMD contribute to identiﬁcation of elevated fracture risk (EFR) in postmenopausal breast
cancer patients treated with AIs.
Methods: 100 patients with early stage hormone-positive breast cancer treated with AIs, no prior BMAs, and with
serial DXAs were identiﬁed. BMD and TBS were measured from DXA images before and following initiation of AIs,
and FRAX® scores were calculated from review of clinical records. EFR was deﬁned as either: BMD ≤−2.5 or BMD
between −2.5 and −1 plus either increased risk by FRAX® or degraded microstructure by TBS.
Results: At baseline, BMD alone identiﬁed 4% of patients with EFR. The addition of FRAX® increased detection
to 13%, whereas the combination of BMD, FRAX® and TBS identiﬁed 20% of patients with EFR. Following AIs,
changes in TBS were independent of changes in BMD. On follow-up DXA, BMD alone detected an additional 1
patient at EFR (1%), whereas BMD+ FRAX® identiﬁed 3 additional patients (3%), and BMD+FRAX®+TBS
identiﬁed 7 additional patients (7%).
Conclusions: The combination of FRAX®, TBS, and BMD maximized the identiﬁcation of patients with EFR.
TBS is a novel assessment that enhances the detection of patients who may beneﬁt from BMAs.
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1. Introduction
Aromatase-Inhibitors (AIs) are commonly used in the treatment of
post-menopausal women with a history of hormone receptor-positive
breast carcinoma, and have been shown to decrease bone mineral
density (BMD) and increase the risk of bone fragility fractures [1].
The National Comprehensive Cancer Network Task Force (NCCN)
currently recommends screening of fracture risk in all patients initiat-
ing AIs by obtaining clinical history, dual-energy X-ray absorptiometry
(DXA) scans and with the use of the fracture risk assessment tool
(FRAX®) calculator. If T-score is less than or equal to −2.0 at any site or
if the FRAX® 10-year absolute risk of fracture is greater than 20% for
any major fracture or greater than 3% for hip fracture, bone modifying-
agents (BMAs) such as bisphosphonates or denosumab, are recom-
mended. For women with increased risk of fractures initiating AI
therapy, BMAs such as bisphosphonates or denosumab can be recom-
mended, both which have been shown to decrease the risk of bone
fracture in the setting of AI therapy [2,3]. The current gold standard
screening tool for the diagnosis of osteoporosis in the absence of
fragility fractures is DXA.
Many patients without osteoporotic BMD suﬀer fragility fractures.
It is important to highlight that the majority of fractures actually occur
in patients with a T-score above the osteoporotic range [4], making the
osteoporosis threshold (BMD T score < 2.5) inadequate to identify all
patients at risk. Furthermore, BMD does not evaluate the degree of
bone microarchitectural deterioration, which may represents an in-
dependent factor contributing to increased bone fragility [5].
The trabecular bone score (TBS) is an innovative gray-level texture
measurement that utilizes lumbar spine DXA images to discriminate
changes in bone microarchitecture [6]. Speciﬁcally, TBS measures
tridimensional bone areas with diﬀerent trabecular and microstructur-
al characteristics. TBS has been shown to be an independent indicator
of increased fracture risk [7]. Furthermore, the combination of TBS
microstructure evaluation with BMD measured by DXA has been
shown to be superior to either measurement alone in the assessment
of fracture risk [8].
In an eﬀort to optimize the identiﬁcation of postmenopausal
women treated with adjuvant AIs at risk of bone fragility fractures,
we evaluated a screening model that integrates the novel TBS tool with
FRAX® and DXA. We then studied if our tools represent independent
variables in this clinical context, and enumerated the relative contribu-
tion of adding TBS to the standard screening approaches most
commonly observed in the clinic (BMD± FRAX®).
2. Materials and methods
2.1. Patient selection
Patients were identiﬁed via institutional databases at Memorial
Sloan Kettering Cancer Center under an Institutional Review Board
waiver of consent. Using DataLine services we identiﬁed 309 unique
patients who were diagnosed with breast cancer at MSKCC between the
years of 2005 and 2012, who were post-menopausal (deﬁned as ≥60
years old or ≥50 years old with amenorrhea for > 12 months), were
treated with an AI, and who had at least 2 DXAs performed at MSKCC.
Through a chart review, we then eliminated patients who were treated
with BMAs prior to baseline or follow-up DXA. We also excluded all
patients with a BMI over 37, as TBS has not been validated in this
population. We then selected the patients who had a baseline DXA
within 3 months of starting the AI, and a follow up DXA more than 6
months but less than 36 months after the ﬁrst one. This search yielded
to 100 unique patients who were included in our analysis.
2.2. BMD, TBS, and FRAX assessment
As per standard-of-care at MSKCC, BMD from femoral neck, total
hip and lumbar spine was measured by DXA (GE-lunar). TBS
measurements were performed in the Bone Disease Center at the
Lausanne University Hospital (CHUV), Lausanne, Switzerland (TBS
iNsight® Software version 1.8, Med-Imaps, Pessac, France) using
anonymized spine DXA ﬁles to ensure blinding of the Swiss investiga-
tors to all clinical parameters and outcomes. The approach was similar
to the one used in other studies [7]. BMD and TBS were evaluated at
baseline and at follow-up. FRAX® score was calculated utilizing the
clinical information from patients’ charts, and using the online algo-
rithm [9].
BMD was interpreted using World Health Organization (WHO)
guidelines, which deﬁne risk according to T-score, which is the
standard deviation diﬀerence between a patient's BMD and that of a
young-adult reference population. A T-score of ≤−2.5 indicates clinical
osteoporosis. Osteopenia is deﬁned as a borderline T-score (between
−1.0 and −2.5), whereas normal BMD is deﬁned as T-score > −1.0.
TBS, being a continuous variable as BMD, was interpreted using the
tertile approach extracted from the fracture data of a large Canadian
cohort. Degraded microarchitecture represents the highest risk, and is
deﬁned as a TBS value of ≤1.2. Partially degraded microarchitecture
represents borderline risk, and is deﬁned as values between 1.2 and
1.35, whereas normal microarchitecture is deﬁned as TBS ≥1.35 [6,7].
FRAX® assessment was conducted via retrospective medical records
review and calculated through the online algorithm (https://www.shef.
ac.uk/FRAX).
2.3. Deﬁnition of at-risk populations
Using BMD, TBS, and FRAX®, we evaluated three screening
paradigms for identifying patients with high fracture risk who would
be suitable for pharmacologic therapy with a BMA. The ﬁrst screening
paradigm is BMD alone using osteoporosis (T≤−2.5) as a threshold for
positivity. The National Osteoporosis Foundation recommends BMA
therapy for this population based upon models that predict a favorable
cost-beneﬁt ratio [10].
The second screening paradigm is BMD plus FRAX®, which is the
standard screening practice endorsed by the National Comprehensive
Cancer Network (NCCN) and National Osteoporosis Foundation [10].
For BMD plus FRAX®, the threshold for positivity is either osteoporosis
by BMD, or osteopenia by BMD plus a FRAX 10-year probability of a
hip fracture ≥3% or a 10-year probability of a major osteoporosis-
related fracture ≥20%. These thresholds were determined based upon
modeling predicting favorable cost-beneﬁt ratio, speciﬁc to the United
States population [10].
Finally, we tested a novel screening paradigm of BMD plus FRAX®
plus TBS. For this method, we deﬁned positivity to elevated fracture
risk (EFR) as either: 1) osteoporosis by BMD (T-score ≤−2.5); 2)
osteopenia + high FRAX® score (as above); or 3) osteopenia + low TBS
score (degraded microarchitecture, i.e. TBS ≤1.2).
2.4. Statistical analysis
Statistical analysis was performed using IBM Statistical Package for
the Social Sciences (SPSS)®. 0.05 was set as a threshold for statistical
signiﬁcance. Kolmogorov-Smirnov test ascertained normal distribution
of data. Pearson's correlation was calculated to assess the association
between TBS and BMD, one-way repeated measure ANOVA (using
Mauchly's test to assess assumption of sphericity) and simple linear
regression to assess prediction of TBS total percentage change by TBS
at baseline, BMI, race, age at beginning of treatment, DXA interval and
type of AI. All comparisons were two-tailed.
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3. Results
3.1. Subject characteristics
Baseline demographic and clinical characteristics, as well as TBS
and lumbar spine (LS) BMD values, are summarized in Table 1.
Median age was 67 years (range 51–87 years) and median BMI was
27.5 kg/m2 (range 18.8–36.6 kg/m2). The majority of patients were
treated with a non-steroidal AI (95%: 70, anastrozole; 24, letrozole; 1,
letrozole followed by anastrozole), whereas 5% of patients were treated
with a steroidal AI (5, exemestane).
At baseline, 45 subjects had normal BMD (45%), 51 subjects met
WHO criteria for osteopenia (51%), and 4 subjects met criteria for
osteoporosis (4%). By TBS, 33 subjects had normal bone microarch-
itecture (33%), whereas 47 subjects had partially degraded microarch-
itecture (47%) and 20 subjects had degraded microarchitecture (20%)
(Fig. 1).
3.2. Analysis of combined screening approach of BMD+FRAX+TBS at
baseline
We assessed the ability of the three screening approaches (BMD
alone, BMD + FRAX®, or combined BMD + FRAX® + TBS) to identify
post-menopausal breast cancer patients at risk of fragility fracture. At
baseline DXA, only 4% of patients (n=4/100) met criteria for EFR by
BMD alone corresponding to a number needed to screen
(NNS=#screened /#diagnosed) of 25. With the addition of the FRAX®
assessment tool, 13% of patients (n=13/100) met criteria for EFR,
corresponding to a NNS of 8. Finally, with the combined approach
including TBS, 20% of patients (n=20/100) met criteria for EFR,
corresponding to a NNS of 5. Fig. 2a illustrates the breakdown of how
subjects are classiﬁed according to each of the screening approaches.
3.3. Analysis of combined screening approach of BMD+FRAX®+TBS
during AI therapy
We then evaluated the ability of each of the screening approaches to
detect AI-associated fracture risk among patients who did not have
EFR at baseline. In this data series, follow-up DXA was performed on
average 21 months following initiation of AI (12–35 months). Eighty
subjects did not exhibit EFR at baseline. At follow-up, one additional
subject developed EFR by BMD criteria, versus an additional 3 subjects
by BMD + FRAX® criteria, versus an additional 7 subjects by BMD +
FRAX® + TBS criteria. Despite less profound percentage changes in
TBS on average across all patients, changes in TBS were more likely to
inﬂuence the determination of EFR following initiation of AI. Fig. 2b
illustrates the breakdown according to each of the screening ap-
proaches. In summation, a BMD-only screening approach with baseline
and follow-up DXA exhibited a NNS of 20, versus NNS of 6 for BMD
plus FRAX®, versus NNS of 4 for BMD plus FRAX ®plus TBS.
3.4. Eﬀect of AI on TBS and BMD
AI therapy was associated with statistically signiﬁcant declines in
lumbar spine BMD (mean annual decline: −0.45 T-score units, or
−1.5%; p < 0.001) but not in TBS (mean annual decline: −0.15 units, or
−0.5%, NS).
Neither age, ethnicity, BMI, nor AI type appeared to inﬂuence
baseline BMD, TBS, or changes in BMD or TBS following AI (Table 1).
However, the TBS score at baseline inﬂuenced the likelihood of TBS
declines associated with AI therapy: subjects with low TBS scores at
baseline (as deﬁned by degraded microarchitecture, i.e. TBS ≤1.2) were
less likely to experience further declines in TBS, whereas subjects with
normal TBS at baseline were more likely to experience declines in TBS.
This ﬁnding reached statistical signiﬁcance (p < 0.1), with mean
percentage declines of normal TBS group being −3.7%, versus −0.9%
in the partially degraded microarchitecture group and +3.9% in the
degraded microarchitecture group. Conversely, declines in BMD did
not appear to be inﬂuenced by baseline BMD.
3.5. BMD and TBS are diﬀerentially inﬂuenced by AI therapy
We then evaluated whether BMD and TBS were independent
variables in this dataset. Fig. 1 illustrates the correlation between TBS
values and lumbar spine BMD, with each data point representing an
individual DXA scan. We observed a weak positive relationship between
BMD and TBS (Pearson r=0.19, p=0.007), indicating that subjects with
preserved BMD may be more likely to have non-degraded bone micro-
architecture. We next evaluated for correlations in changes in BMD
versus TBS following initiation of AI. To control for variations in the time
interval between serial DXA scans, we plotted the annual percentage
change in BMD versus the annual percentage change in TBS. With this
approach, we found no correlation in change in BMD versus change in
TBS (Pearson r=0.07, NS), suggesting that AI may diﬀerentially inﬂuence
BMD versus TBS within individual patients. Furthermore, no correla-
tions were identiﬁed when repeated for absolute annual change (i.e.
change in BMD/yr versus change in TBS/yr), or non-adjusted changes
(i.e. change in BMD versus change in TBS, or % change in BMD versus %
change in TBS) (data not shown).
Table 1
Trends in BMD and TBS, organized by clinical and demographic characteristics.
Group LS BMD,
Baseline
TBS,
Baseline
TH BMD,
baseline
ΔLS
BMD/yr
ΔTBS/yr
All Patients −0.04 1.29 −0.39 −0.45
(−1.5%)
−0.15
(−0.5%)
Age
≤65 y (n=39) −0.08 1.32 −0.17 −0.12
(−1.2%)
−0.01
(−0.8%)
> 65 (n=61) −0.01 1.27 −0.52 −0.14
(−1.7%)
−0.01
(−0.3%)
BMI
BMI≤25
(n=30)
−0.51 1.3 −0.73 −0.16
(−1.3%)
−0.01
(−0.6%)
BMI > 25
(n=70)
0.16* 1.28 −0.24 −0.12
(−1.5%)
−0.01
(−0.4%)
Ethnicity
Caucasian
(n=51)
−0.23 1.32 −0.7 −0.15
(−2.3%)
−0.01
(−0.9%)
Other (n=49) 0–17 1.26 −0.05 −0.12
(−1.9%)
0.00 (0%)
AI type
Anastrozole
(n=70)
−0.06 1.29 −0.44 −0.12
(−1.3%)
−0.01
(−0.8%)
Exemestane
(n=5)
−0.24 1.32 0.22 −0.24
(−2.8%)
−0.02
(−1.4%)
Letrozole
(n=24)
0.34 1.27 −0.39 −0.17
(−1.7%)
0.01
(0.9%)
Baseline LS BMD
T≤−1.0 (n=35) −1.71 1.26 −1.03 −0.09
(1.8%)
−0.01
(−0.2%)
T > −1.0 (=65) 0.86* 1.3 −0.05 −0.16
(1.3%)
−0.01
(−0.6%)
Baseline TBS
TBS≤1.35
(n=68)
−0.24 1.22 −0.49 −0.14
(−1.3%)
0.02
(0.4%)
TBS > 1.35
(n=32)
0.39 1.43* −0.18 −0.11
(−1.8%)
0.03
(−2.2%)*
Legend: LS, lumbar spine; BMD, bone mineral density; TBS, trabecular bone score; Δ,
change; y, year; AI, aromatase inhibitor.
* p < 0.05/
V. Mariotti et al. Journal of Bone Oncology  (xxxx) xxxx–xxxx
3
3.6. The majority of cases of EFR are detected when follow-up DXAs
are performed greater than 18 months following initiation of AI
Substantial heterogeneity exists in clinical practice with regards to
the timing of repeat DXA following the initiation of AI. In our dataset,
we wished to ascertain and compare the rate of detection of acquired
EFR with an early detection strategy (i.e. DXA within 18 months of AI
initiation) versus a delayed detection strategy (i.e. DXA > 18 months
following AI initiation). Excluding patients who had high fracture risk
at baseline, 30% of subjects (n=24/80) were evaluated with an “early”
DXA (interval range 11–18 months, average 13.8, SD 2.2), whereas
70% of subjects (n=56/80) were evaluated with a “delayed” DXA
(interval range 18–35 months, average 24.5, SD 3.2). In the early DXA
group, only one subject (4%) developed EFR following AI (as identiﬁed
by a decrease in TBS). Contrastingly, the majority of EFR was detected
in the delayed DXA group, with 6 patients detected (11%) ( Fig. 3).
These data correspond with a NNS of 24 associated with early DXA
scans, versus 13 for delayed DXA scans.
4. Discussion
Patients treated with AIs are at increased risk of fragility fractures,
and BMD assessment alone is unable to identify all patients at risk.
Recently, numerous alternative risk-assessment tools have been devel-
oped to better estimate fracture risk, which may allow for a more
eﬃcient preventative approach in patients receiving AI.
The most extensively validated tool is the FRAX®, a computer-based
algorithm that calculates risk of fracture based on BMD and clinical
factors [11]. In the setting of AI therapy, FRAX® facilitates the decision
of whether to administer BMAs in women with borderline BMD
(osteopenia). A major advantage of FRAX® is that it utilizes readily-
available clinical information. FRAX®, however does not speciﬁcally
assess the risk of fracture in women with breast cancer treated with AIs
and may underestimate their eﬀects on bone [12].
Furthermore, methodologies that assess bone quality and predict
fracture risk have emerged. A large body of evidence validates the
utility of TBS in predicting fragility fracture [13,14]. In the largest
longitudinal series, the Manitoba study, TBS and BMD were evaluated
in 29,407 women ( > 50 years of age) and followed for fragility
fractures. With a median follow up of 4.7 years, TBS emerged as a
highly signiﬁcant predictor of fracture. Women with osteopenia and
low TBS values exhibited fracture rates on par with that of women with
osteoporosis, suggesting that TBS may also help facilitate the decision
to treat with a BMA [7]. Such ﬁndings were corroborated in an
international meta-analysis of 14 studies (excluding the Manitoba
cohort) — together incorporating 17,809 men and women (59%
women) ranging in age from 40 to 90 years (mean age 72). The
gradient of risk per standard deviation decrease of TBS for hip fracture
or other major osteoporotic fracture (clinical spine, distal forearm or
proximal humerus fracture) ranged from 1.31 to 1.54 depending on age
and fracture outcome with no diﬀerence between men and women.
Such level of risk remained signiﬁcant even after adjustment for both
spine BMD and clinical risk factors [8].
We conducted a retrospective analysis to compare a BMD-alone
strategy, versus BMD+FRAX® and BMD+FRAX®+TBS screening stra-
tegies. To our knowledge, this constitutes the ﬁrst study to assess the
relative contributions of FRAX® and TBS. In our cohort, FRAX®+BMD
identiﬁed 9 (9%) additional patients at increased risk for fractures at
baseline and 2 (2%) after AI treatment compared to BMD alone, thus
corroborating the current National Comprehensive Cancer Network
and National Osteoporosis Foundation guidelines to conduct FRAX®
assessment in osteopenic women who require AI [10]. Likewise, the
addition of TBS increased the numbers of at-risk patients detected both
at baseline (an additional 16, 16%) and at follow-up (an additional 6,
6%) compared to BMD alone.
Consistent with other reports [15,16], the eﬀect of AI on TBS did
not appear to correlate with changes in BMD, suggesting that these two
risk assessments may be complementary rather than overlapping, and
could potentially be combined to create a more sensitive measure of
bone fragility. Our conclusions are corroborated by two small previous
studies evaluating the inﬂuence of AI on TBS. In one study, 34 breast
Fig. 1. Correlations of BMD with TBS. A: Correlation of intra-patient BMD (lumbar spine) versus TBS at baseline; B: Correlation of changes in BMD versus TBS over time, calculated as
annual rate of change. Legend: BMD, bone mineral density; TBS, trabecular bone score.
Fig. 2. Detection of EFR using various screening strategies. A: Distribution of EFR
patients detected on baseline DXA, by BMD alone, BMD+FRAX®, or BMD+FRAX®+TBS;
B: Distribution of EFR detected on follow-up DXA. Legend: DXA, dual-energy X-ray
absorbimetry; BMD, bone mineral density; FRAX®, fracture risk assessment tool; TBS,
trabecular bone score. Gray boxes indicate designation of EFR.
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cancer patients treated with AI were evaluated with both BMD and
TBS, and sustained a decrease of 5.9% and 2.1%, respectively, across a
mean DXA interval of 2.1 years (corresponding to a rate of loss of 2.8%
and 1% annually) [15]. Another study evaluated the eﬀect of exemes-
tane on TBS in 19 patients, and showed a TBS decrease of 2.3% at 24
months (corresponding to a mean annual decrease of 1.2%) [16]. These
ﬁndings are generally consistent with our study, which demonstrated
mean annual decreases of 1.5% for BMD and 0.5% for TBS.
One unique ﬁnding from our dataset is that subjects with normal
TBS at baseline are more likely to experience declines in TBS, whereas
subjects with low TBS at baseline do not experience further declines.
We speculate that this ﬁnding may reﬂect variations in sensitivity of the
measurement assay across high versus low TBS ranges, and indicate
that the TBS measurement platform may have highest sensitivity for
detecting changes in the normal range. This ﬁnding, combined with the
ﬁnding that TBS contributed the most to identifying patients’ AI-
associated fracture risk, supports a practice of obtaining serial TBS
measurements in patients with normal TBS at baseline, but may argue
that serial measurement in patients with low TBS is less informative, as
this population might already be at high risk of fracture.
In our study, the decline in TBS during AIs treatment was not
statistically signiﬁcant. Changes in TBS after osteoporosis therapy are
known to be of lesser magnitude than corresponding changes in BMD;
conversely, it is possible that BMD losses in the setting of AI therapy
occur in similar fashion [13]. Additionally, longer follow up might have
demonstrated the decline in TBS associated with relatively longer use
of AIs (mean 2.1 years) that others have demonstrated [15].
Furthermore, patients in our study with follow up DXA after > 18
months of AI treatment were more likely to experience EFR than < 18
months of follow up. Thus, serial TBS measurements appear to identify
subjects with newly-acquired fracture risk following initiation of AI
therapy with greater sensitivity following 18 months on AI. Future
studies assessing TBS after longer follow up are needed to further
evaluate AI-associated changes in trabecular microstructure over ﬁve to
ten years.
In summary, our analysis supports further evaluation of a screening
approach of BMD+FRAX®+TBS, obtained at baseline and at 2 years
following AI, with special attention paid to patients with osteopenia
and non-degraded bone microarchitecture by TBS. An alternative
approach could be the use of TBS-adjusted FRAX BMD as it has been
recently proposed [8]. This later approach would still have to be tested
in this very speciﬁc population.
Recently published European consensus guidelines suggest that the
use of bisphosphonates should be considered for the prevention of
cancer treatment-induced bone loss in all patients with a T-score of
< −2.0 [17]. According to this approach, 7 additional patients would
have been identiﬁed at baseline in our population based on DXA alone,
of these 2 would have been identiﬁed by the combined approach of
osteopenia + low TBS score, 2 by osteopenia + high FRAX® score, and 1
by both osteopenia + low TBS score and osteopenia + high FRAX®.
Only 28% of patients identiﬁed by the combined approach osteopenia +
low TBS score would have been identiﬁed by lowering the T-score
threshold. This result suggests that modiﬁcation of T-score threshold
would not hamper the usefulness of TBS.
Our ﬁndings should be interpreted in the context of recently
reported phase III studies, evaluating the potential utility of a universal
BMA treatment approach for all post-menopausal women receiving AI.
Recent large randomized studies in adjuvant AI treated breast cancer
patients have demonstrated, respectively: an improvement in BMD
with risedronate, as well as both an improvement in BMD plus a
reduction in fragility fractures with denosumab [18]. (Gnant et al., n.d.)
These ﬁndings, while clearly demonstrating the clinical utility of BMAs,
do not obviate the importance of ﬁnding better strategies to identify
patients at risk of fragility fractures. An approach of universally
treating all patients starting therapy with an AI with a BMA has not
been adopted. Indeed, the majority of women will not experience a
fragility fracture, and therefore a universal treatment approach would
lead to overtreatment with BMAs, which may be costly and associated
with toxicities. When considering extended treatment with BMAs, rare
adverse eﬀects such as atypical femur fractures and osteonecrosis of the
jaw, likely related to duration of use, should be taken in consideration
[19]. An eﬀective screening approach may serve to better identify
patients who may beneﬁt from BMAs.
Our study is limited by the number of subjects and its retrospective
nature. Additionally, an optimal TBS threshold for determining risk has
not been ﬁrmly established. The TBS categories used in our study have
been recently proposed by an international working group of TBS
users, and correspond to the tertiles for fracture risk as deﬁned in a
recent meta-analysis by McCloskey et al. In this study the thresholds of
1.23 and 1.31 deﬁned high risk and intermediate risk respectively, as
the risk for major osteoporotic fracture were signiﬁcantly higher in the
highest and intermediate tertile compared with the lowest-risk tertile
(TBS > 1.31) [8,20]. (“MEDIMAPS-UK-WEB.pdf,” n.d).
5. Conclusion
In conclusion, our retrospective analysis demonstrates that TBS
combined with the standard-of-care risk assessment tools BMD +
FRAX® may identify additional patients at high risk of fragility fracture
both before and during treatment with AIs, who may beneﬁt of
treatment with BMAs.
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assessment tool; TBS, trabecular bone score.
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